| Product Name | Tesirine | SG3249 | 
|---|---|
| CAS | 1595275-62-9 | 
| Formula | C75H101N9O23 | 
| MW | 1496.65 | 
| Appearance | White to light yellow powder | 
| Storage condition | Avoid light, nitrogen, -20 ℃ | 
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity | 
|---|---|---|---|---|
| 1 mg | 3-5days | ¥21660.00 | Visible after login | |
| 5 mg | 3-5days | ¥46360.00 | Visible after login | 
| Product Name | Tesirine | SG3249 | 
|---|---|
| CAS | 1595275-62-9 | 
| Formula | C75H101N9O23 | 
| MW | 1496.65 | 
| Appearance | White to light yellow powder | 
| Storage condition | Avoid light, nitrogen, -20 ℃ | 
Tesirine (SG-3249; SG3249), cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer used as an antibody-drug conjugate (ADC) payload; Tesirine was designed to combine the potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. Rovalpituzumab tesirine is a first-in-class ADC directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in small-cell lung cancer.
PMID: 27882195 PMCID: PMC5108040 DOI: 10.1021/acsmedchemlett.6b00062
PMID: 29992976 PMCID: PMC6041317 DOI: 10.1038/s41598-018-28533-4